Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

RNTX Rein Therapeutics Inc.

Price (delayed)

$2

Market cap

$44.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.17

Enterprise value

$36.88M

Highlights
The EPS is up by 10% since the previous quarter
Rein Therapeutics's net income has increased by 2.6% from the previous quarter
RNTX's quick ratio has shrunk by 53% YoY and by 45% QoQ
Rein Therapeutics's equity has decreased by 45% YoY and by 8% QoQ

Key stats

What are the main financial stats of RNTX
Market
Shares outstanding
22.15M
Market cap
$44.31M
Enterprise value
$36.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$63.52M
Net income
-$61.27M
EBIT
-$62.82M
EBITDA
-$62.81M
Free cash flow
-$23.2M
Per share
EPS
-$3.17
EPS diluted
-$3.17
Free cash flow per share
-$1.06
Book value per share
$2.3
Revenue per share
$0
TBVPS
$0.42
Balance sheet
Total assets
$57.63M
Total liabilities
$7.75M
Debt
$0
Equity
$49.88M
Working capital
$2.35M
Liquidity
Debt to equity
0
Current ratio
1.39
Quick ratio
1.24
Net debt/EBITDA
0.12
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-73.5%
Return on equity
-81.6%
Return on invested capital
N/A
Return on capital employed
-121.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNTX stock price

How has the Rein Therapeutics stock price performed over time
Intraday
-0.99%
1 week
2.04%
1 month
9.89%
1 year
-36.1%
YTD
-13.04%
QTD
12.99%

Financial performance

How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.52M
Net income
-$61.27M
Gross margin
N/A
Net margin
N/A
Rein Therapeutics's net income has increased by 2.6% from the previous quarter
The operating income has increased by 2.5% since the previous quarter

Price vs fundamentals

How does RNTX's price correlate with its fundamentals

Growth

What is Rein Therapeutics's growth rate over time

Valuation

What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 10% since the previous quarter
Rein Therapeutics's equity has decreased by 45% YoY and by 8% QoQ
RNTX's P/B is 33% below its 5-year quarterly average of 1.3 but 9% above its last 4 quarters average of 0.8

Efficiency

How efficient is Rein Therapeutics business performance
The ROE has plunged by 141% YoY and by 11% from the previous quarter
The ROA has plunged by 136% YoY and by 10% from the previous quarter

Dividends

What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNTX.

Financial health

How did Rein Therapeutics financials performed over time
RNTX's quick ratio has shrunk by 53% YoY and by 45% QoQ
RNTX's current ratio has dropped by 51% year-on-year and by 42% since the previous quarter
The debt is 100% smaller than the equity
Rein Therapeutics's equity has decreased by 45% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.